Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection

Current Urology Reports

Volumn 14, Issue 5, 2013, Pages 511-517

  Pearce, Shane ^a   Steinberg, Zoe ^a   Eggener, Scott ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Minimally invasive; Modified template; Nerve sparing; Nonseminomatous germ cell tumor; Retrograde ejaculation; Retroperitoneal lymph node dissection; Robotic; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTEGRADE EJACULATION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE INFERTILITY; MINIMALLY INVASIVE SURGERY; NON SEMINOMATOUS GERMINOMA; PATIENT SELECTION; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; RETROGRADE EJACULATION; RISK BENEFIT ANALYSIS; RISK FACTOR; SURGICAL APPROACH; TERATOMA; TESTIS CANCER; TREND STUDY; TUMOR LOCALIZATION; WIDE EXCISION;

EQUIPMENT DESIGN; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; RETROPERITONEAL SPACE; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84886783210     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0366-1     Document Type: Article

References (42)

1. Jemal A et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Stephenson AJ, Klein EA. Surgical management of low-stage nonseminomatous germ cell testicular cancer. BJU Int. 2009;104(9 Pt B):1362-8.
3. Stephenson AJ et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23(12):2781-8.
4. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009;181(2):627-32. discussion 632-3.
5. Baniel J et al. Complications of primary retroperitoneal lymph node dissection. J Urol. 1994;152(2 Pt 1):424-7.
6. Pettus JA et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2009;73(2):328-31. discussion 331-2.
7. Sheinfeld J. Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology. 1994;44(1):2-14.
8. Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol. 2003;21(2):129-32.
9. Roberts JB. VII. Excision of the lumbar lymphatic nodes and spermatic vein in malignant disease of the testicle: a contribution from the surgical laboratory of the Philadelphia polyclinic. Ann Surg. 1902;36(4):539-49.
10. Hinman F. The operative treatment of tumors of the testicle. JAMA. 1914;63:2009-15.
11. Patton JF, Hewitt CB, Mallis N. Diagnosis and treatment of tumors of the testis. J Am Med Assoc. 1959;171:2194-8.
12. Skinner DG, Leadbetter WF. The surgical management of testis tumors. J Urol. 1971;106(1):84-93.
13. Busch FM, Sayegh ES. Roentgenographic visualization of human testicular lymphatics: a preliminary report. J Urol. 1963;89:106-10.
14. Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am. 1977;4(3):509-21.
15. Ray B, Hajdu SI, Whitmore Jr WF. Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. 1974;33(2):340-8.
16. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315-20.
17. Weissbach L, Boedefeld EA. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol. 1987;138(1):77-82.
18. Lange PH, Narayan P, Fraley EE. Fertility issues following therapy for testicular cancer. Semin Urol. 1984;2(4):264-74.
19. •• Donohue JP, et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol, 1993. 149(2): 237-43. This paper from Indiana University provides long-term oncologic and functional outcomes following primary RPLND. It specifically describes reductions in ejaculatory dysfunction achieved with modified templates and prospective nerve sparing.
20. Jewett MA et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220-4.
21. Donohue JP et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 Pt 1):287-91. discussion 291-2.
22. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol. 1985;134(3):485-9.
23. Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol. 1990;144(5):1160-3.
24. Weissbach L, Boedefeld EA, Horstmann-Dubral B. Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Final results of a prospective multicenter trial 1982-1987. Testicular Tumor Study Group. Eur Urol. 1990;17(2):97-106.
25. Oldenburg J et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21(17):3310-7.
26. Debono DJ et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15(4):1455-64.
27. Baniel J et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153(3 Pt 2):976-80.
28. Coogan CL et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol. 1996;156(5):1656-8.
29. Beck SD et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer. 2007;110(6):1235-40.
30. Steiner H, Peschel R, Bartsch G. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int. 2008;102(3):310-4.
31. Carver BS et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25(9):1033-7.
32. Janetschek G et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol. 2000;163(6):1793-6.
33. Nielsen ME et al. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology. 2007;70(6):1168-72.
34. • Hyams ES, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol. 187(2): p. 487-92. This retrospective review of 91 patients undergoing laparoscopic RPLND at Johns Hopkins demonstrates feasibility, safety, and short-term oncologic effectiveness for clinical stage 1 NSGCTs.
35. Doerr A, Skinner EC, Skinner DG. Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol. 1993;149(6):1472-4.
36. Rassweiler JJ et al. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol. 2008;54(5):1004-15.
37. Carver BS, Sheinfeld J. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol. 2005;2(7):330-5.
38. Kenney PA, Tuerk IA. Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer. World J Urol. 2008;26(6):561-9.
39. • Eggener SE, et al. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol, 2007. 177(3): 937-42; discussion 942-3. This large anatomic review of 191 patients with pathologic stage II disease describes potentially significant rates of disease outside the limits of modified templates.
40. Carver BS et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007;25(28):4365-9.
41. Sharp DS et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008;26(34):5524-9.
42. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006;4(10):1059-70.